Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

Gerd Horneff,Daniel Alvarez,Nico Wulffraat,Richard Mouy,Joseph Wajdula,Ingrīda Rumba-Rozenfelde ,Zbigniew Żuber ,C Job-Deslandre ,Katarzyna Kobusińska ,Rubén Burgos‐Vargas ,Vyacheslav Chasnyk ,T Constantin ,Deborah A Woodworth ,Gordana Sušić ,Alberto Martini,Valda Staņēviča ,Luciana Breda,Pavla Doležalová ,Joke Dehoorne,Ivan Foeldvari,Bonnie Vlahos,Jelena Vojinović ,Chuanbo Zang,Violeta Panavienė ,Nicolino Ruperto

doi:10.1136/annrheumdis-2012-203046

Abstract

ObjectiveTo investigate the efficacy and safety of etanercept (ETN) in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).MethodsCLIPPER is an ongoing, Phase...

Full Text